Preticks
.
Follow Us
TR
News Details
Satsuma Pharmaceuticals Announces Enrollment of First Patient in the ASCENDâ„¢ Phase 3 open-label, safety trial of STS101
About Satsuma Pharmaceuticals, Inc.
NASDAQ: $STSA
Notified: $25.78
16:01 EDT
Price Chart